Psoriatic Skin Lesions after Apalutamide Treatment
Abstract is missing (Short communication)
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018; 378: 1408-1418.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019; 381: 13-24.
Schwarz W, Schell H, Hornstein OP. Testosterone serum levels in male psoriatics. Arch Dermatol Res 1981; 270: 377-379.
Cemil BC, Cengiz FP, Atas H, Ozturk G, Canpolat F. Sex hormones in male psoriasis patients and their correlation with the Psoriasis Area and Severity Index. J Dermatol 2015; 42: 500-503.
Allam JP, Bunzek C, Schnell L, Heltzel M, Weckbecker L, Wilsmann-Theis D et al. Low serum testosterone levels in male psoriasis patients correlate with disease severity. Eur J Dermatol 2019; 29: 375-382.
Rathkopf DE, Scher HI. Apalutamide for the treatment of prostate cancer. Expert Rev Anticancer Ther 2018; 18: 823-836.
Shima K, Nomura T, Yamada Y, Usui S, Kobayashi T, Kabashima K. Maculopapular-type drug eruptions caused by apalutamide: case series and a review of the literature. J Eur Acad Dermatol Venereol 2022; 36: e113-e115.
How to Cite
Copyright (c) 2022 Fumi Miyagawa, Nobuya Akioka, Noriko Yoshida, Kohei Ogawa, Hideo Asada
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.